Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: A post-hoc analysis

Breast

Volumn 20, Issue 5, 2011, Pages 468-474

  Aapro, Matti ^a   Tjulandin, Sergei ^b   Bhar, Paul ^c   Gradishar, William ^d  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c CELGENE CORPORATION   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Elderly; Metastatic breast cancer; Paclitaxel

Indexed keywords

DOCETAXEL; NANOPARTICLE ALBUMIN BOUND PACLITAXEL; PACLITAXEL; UNCLASSIFIED DRUG;

AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MYALGIA; NEUTROPENIA; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY;

EID: 80052429731     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.07.005     Document Type: Article

References (25)

1. Ries L., Eisner M.P. Cancer of the female breast. SEER survival monograph: cancer survival among adults: US SEER program, 1988-2001, patient and tumor characteristics 2007, National Cancer Institute, 101-110.
2. Bernardi D., Errante D., Gallligioni E., Crivellari D., Bianco A., Salvagno L., et al. Treatment of breast cancer in older women. Acta Oncol 2008, 47:187-198.
3. Crivellari D., Aapro M., Leonard R., von Minckwitz G., Brain E., Goldhirsch A., et al. Breast cancer in the elderly. J Clin Oncol 2007, 25:1882-1890.
4. John V., Mashru S., Lichtman S. Pharmacological factors influencing anticancer drug selection in the elderly. Drugs Aging 2003, 20:737-759.
5. Thomas G.A., Leonard R.C.F. How age affects the biology of breast cancer. Clin Oncol 2009, 21:81-85.
6. Singh R., Hellman S., Heimann R. The natural history of breast carcinoma in the elderly. Cancer 2004, 100:1807-1813.
7. Wildiers H., Kunkler I., Biganzoli L., Fracheboud J., Vlastos G., Bernard-Marty C., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007, 8:1101-1115.
8. Conlin A.K., Seidman A.D. Taxanes in breast cancer: an update. Curr Oncology Reports 2007, 9:22-30.
9. Friedrich M., Diesing D., Villena-Heinsen C., Felberbaum R., Kolberg H.C., Diedrich K. Taxanes in the first-line chemotherapy of metastatic breast cancer: review. Eur J Gynaecol Oncol 2004, 25:66-70.
10. Taxol full prescribing information 2007, Available from. http://packageinserts.bms.com/pi/pi_taxol.pdf.
11. Taxotere full prescribing information 2010, Available from. http://products.sanofi-aventis.us/Taxotere/taxotere.html.
12. Wildiers H., Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004, 30:333-342.
13. Gelderblom H., Verweij J., Nooter K., Sparreboom A., Cremophor E.L. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598.
14. Kiessling F., Fink C., Hansen M., Bock M., Sinn H., Schrenk H.H., et al. Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas: use of a low-loaded, covalently bound Gd-Hsa conjugate as contrast agent with high tumor affinity. Invest Radiol 2002, 37:193-198.
15. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
16. Gradishar W.J., Krasnojon D., Cheporov S., Makhson A.N., Manikhas G.M., Clawson A., et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009, 27:3611-3619.
17. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
18. Gardner E.R., Dahut W.L., Scripture C.D., Jones J., Aragon-Ching J.B., Desai N., et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008, 14:4200-4205.
19. Smorenburg C.H., ten Tije A.J., Verweij J., Bontenbal M., Mross K., van Zomeren D.M., et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 2003, 39:196-202.
20. Nannan Panday V., Huizing M., Van Tellingen O., Hakvoort R., Willemse P., Graeff A., et al. Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel. J Oncol Pharm Pract 1999, 5:83-86.
21. Wasil T., Lichtman S.M. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist 2005, 10:602-612.
22. Fountzilas G., Dafni U., Dimopoulos M.A., Koutras A., Skarlos D., Papakostas P., et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009, 115:87-99.
23. Seidman A.D., Berry D., Cirrincione C., Harris L., Muss H., Marcom P.K., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. J Clin Oncol 2008, 26:1642-1649.
24. Palmeri L., Vaglica M., Palmeri S. Weekly docetaxel in the treatment of metastatic breast cancer. Ther Clin Risk Manag 2008, 4:1047-1059.
25. Rivera E., Mejia J.A., Arun B.K., Adinin R.B., Walters R.S., Brewster A., et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008, 112:1455-1461.